171 related articles for article (PubMed ID: 37832833)
1. Hutchinson-Gilford progeria syndrome: Cardiovascular manifestations and treatment.
Lian J; Du L; Li Y; Yin Y; Yu L; Wang S; Ma H
Mech Ageing Dev; 2023 Dec; 216():111879. PubMed ID: 37832833
[TBL] [Abstract][Full Text] [Related]
2. Vascular Smooth Muscle-Specific Progerin Expression Accelerates Atherosclerosis and Death in a Mouse Model of Hutchinson-Gilford Progeria Syndrome.
Hamczyk MR; Villa-Bellosta R; Gonzalo P; Andrés-Manzano MJ; Nogales P; Bentzon JF; López-Otín C; Andrés V
Circulation; 2018 Jul; 138(3):266-282. PubMed ID: 29490993
[TBL] [Abstract][Full Text] [Related]
3. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.
Rivera-Torres J; Acín-Perez R; Cabezas-Sánchez P; Osorio FG; Gonzalez-Gómez C; Megias D; Cámara C; López-Otín C; Enríquez JA; Luque-García JL; Andrés V
J Proteomics; 2013 Oct; 91():466-77. PubMed ID: 23969228
[TBL] [Abstract][Full Text] [Related]
4. Molecular and Cellular Mechanisms Driving Cardiovascular Disease in Hutchinson-Gilford Progeria Syndrome: Lessons Learned from Animal Models.
Benedicto I; Dorado B; Andrés V
Cells; 2021 May; 10(5):. PubMed ID: 34064612
[TBL] [Abstract][Full Text] [Related]
5. Aging in the Cardiovascular System: Lessons from Hutchinson-Gilford Progeria Syndrome.
Hamczyk MR; del Campo L; Andrés V
Annu Rev Physiol; 2018 Feb; 80():27-48. PubMed ID: 28934587
[TBL] [Abstract][Full Text] [Related]
6. Vascular smooth muscle cell loss underpins the accelerated atherosclerosis in Hutchinson-Gilford progeria syndrome.
Hamczyk MR; Andrés V
Nucleus; 2019 Dec; 10(1):28-34. PubMed ID: 30900948
[TBL] [Abstract][Full Text] [Related]
7. The Molecular and Cellular Basis of Hutchinson-Gilford Progeria Syndrome and Potential Treatments.
Batista NJ; Desai SG; Perez AM; Finkelstein A; Radigan R; Singh M; Landman A; Drittel B; Abramov D; Ahsan M; Cornwell S; Zhang D
Genes (Basel); 2023 Feb; 14(3):. PubMed ID: 36980874
[TBL] [Abstract][Full Text] [Related]
8. Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome.
Finley J
Med Hypotheses; 2018 Sep; 118():151-162. PubMed ID: 30037605
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Progerin Suppression and Lamin A Restoration Rescue Hutchinson-Gilford Progeria Syndrome.
Sánchez-López A; Espinós-Estévez C; González-Gómez C; Gonzalo P; Andrés-Manzano MJ; Fanjul V; Riquelme-Borja R; Hamczyk MR; Macías Á; Del Campo L; Camafeita E; Vázquez J; Barkaway A; Rolas L; Nourshargh S; Dorado B; Benedicto I; Andrés V
Circulation; 2021 Nov; 144(22):1777-1794. PubMed ID: 34694158
[TBL] [Abstract][Full Text] [Related]
10. Hutchinson-Gilford Progeria Syndrome (Hgps) and Application of Gene Therapy Based Crispr/Cas Technology as A Promising Innovative Treatment Approach.
Rajeev M; Ratan C; Krishnan K; Vijayan M
Recent Pat Biotechnol; 2021; 15(4):266-285. PubMed ID: 34602042
[TBL] [Abstract][Full Text] [Related]
11. Hutchinson-Gilford progeria syndrome as a model for vascular aging.
Brassard JA; Fekete N; Garnier A; Hoesli CA
Biogerontology; 2016 Feb; 17(1):129-45. PubMed ID: 26330290
[TBL] [Abstract][Full Text] [Related]
12. Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment.
Villa-Bellosta R; Rivera-Torres J; Osorio FG; Acín-Pérez R; Enriquez JA; López-Otín C; Andrés V
Circulation; 2013 Jun; 127(24):2442-51. PubMed ID: 23690466
[TBL] [Abstract][Full Text] [Related]
13. Progerinin, an Inhibitor of Progerin, Alleviates Cardiac Abnormalities in a Model Mouse of Hutchinson-Gilford Progeria Syndrome.
Kang SM; Seo S; Song EJ; Kweon O; Jo AH; Park S; Woo TG; Kim BH; Oh GT; Park BJ
Cells; 2023 Apr; 12(9):. PubMed ID: 37174632
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging.
Olive M; Harten I; Mitchell R; Beers JK; Djabali K; Cao K; Erdos MR; Blair C; Funke B; Smoot L; Gerhard-Herman M; Machan JT; Kutys R; Virmani R; Collins FS; Wight TN; Nabel EG; Gordon LB
Arterioscler Thromb Vasc Biol; 2010 Nov; 30(11):2301-9. PubMed ID: 20798379
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of vascular aging: What can we learn from Hutchinson-Gilford progeria syndrome?
Del Campo L; Hamczyk MR; Andrés V; Martínez-González J; Rodríguez C;
Clin Investig Arterioscler; 2018; 30(3):120-132. PubMed ID: 29602596
[TBL] [Abstract][Full Text] [Related]
16. Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome.
Díez-Díez M; Amorós-Pérez M; de la Barrera J; Vázquez E; Quintas A; Pascual-Figal DA; Dopazo A; Sánchez-Cabo F; Kleinman ME; Gordon LB; Fuster V; Andrés V; Fuster JJ
Geroscience; 2023 Apr; 45(2):1231-1236. PubMed ID: 35752705
[TBL] [Abstract][Full Text] [Related]
17. Hutchinson-Gilford Progeria Syndrome: Challenges at Bench and Bedside.
Kreienkamp R; Gonzalo S
Subcell Biochem; 2019; 91():435-451. PubMed ID: 30888661
[TBL] [Abstract][Full Text] [Related]
18. Hutchinson-Gilford Progeria Syndrome: Cellular Mechanisms and Therapeutic Perspectives.
Cisneros B; García-Aguirre I; De Ita M; Arrieta-Cruz I; Rosas-Vargas H
Arch Med Res; 2023 Jul; 54(5):102837. PubMed ID: 37390702
[TBL] [Abstract][Full Text] [Related]
19. An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome.
Harhouri K; Frankel D; Bartoli C; Roll P; De Sandre-Giovannoli A; Lévy N
Nucleus; 2018 Jan; 9(1):246-257. PubMed ID: 29619863
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
